Journal Home
Search for

Articles in Press

Return to articles in press list

Time course of prostatic edema post permanent seed implant determined by magnetic resonance imaging

Ron S. Sloboda12Corresponding Author Informationemail address, Nawaid Usmani23, John Pedersen23, Albert Murtha23, Nadeem Pervez23, Don Yee23

Received 14 July 2009; received in revised form 31 August 2009; accepted 17 September 2009. published online 29 January 2010.
Corrected Proof

Abstract 

Purpose

To quantify the time course of postimplant prostatic edema magnitude and spatial isotropy using serial magnetic resonance imaging (MRI).

Methods and Materials

Forty patients with histologic diagnosis of prostate cancer received an iodine-125 seed implant (Day 0) and consented to 1.5-T MRI on Days −1, 0, 14, and 28. Seeds of strength 0.39mCi were placed in a modified peripheral loading pattern to deliver 145Gy to the target volume. MR images consisted of 3–4mm thick axial slices with no gap. The image sets were anonymized and randomized to minimize contouring bias, then contoured by a single radiation oncologist. Contours were reoriented about their center of mass to align the prostate long axis with the superior–inferior (S−I) direction; prostate volumes and dimensions in the left–right (L−R), anterior–posterior (A−P), and S−I directions through the center of mass were calculated.

Results

The average relative edema volume was 1.18±0.14 (1standard deviation) on Day 0 and 1.01±0.15 on Day 30. Between Days 0 and 30, the edema resolved linearly with time on average. Average relative edema dimensions on Day 0 in the L−R, A−P, and S−I directions were 1.01±0.07, 1.11±0.09, and 1.08±0.13, respectively.

Conclusions

As measured using MRI, the average edema magnitude for our study population was ∼20% on Day 0 and resolved linearly with time to ∼0% on Day 30. The edema exhibited spatial anisotropy, the prostate expanding on Day 0 by ∼10% in each of the A−P and S−I directions and by ∼0% in the L−R direction.

1 Department of Medical Physics, Cross Cancer Institute, Edmonton, Alberta, Canada

2 Department of Oncology, University of Alberta, Edmonton, Alberta, Canada

3 Department of Radiation Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada

Corresponding Author InformationCorresponding author. Cross Cancer Institute, Room 0418, 11560 University Avenue, Edmonton, Alberta, Canada T6G 1Z2. Tel.: +780-432-8719; fax: +780-432-8615.

 Note: Parts of this work were presented at the American Brachytherapy Society annual meeting held in Toronto, Canada, May 31–June 2, 2009.

PII: S1538-4721(09)00364-X

doi:10.1016/j.brachy.2009.09.008